Welcome to the Working Group on New TB Drugs Blog
TB R&D Weekly Update: Tailoring TB Treatment Based on Host Genotype?
This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes. Additional links to TB R&D news are included.
News from the 21st Stop TB Partnership Coordinating Board Meeting, Bangkok
he 21st Stop TB Partnership Coordinating Board retreat and meeting officially started in Bangkok, Thailand, on Sunday, January 29th with the official opening ceremony held yesterday January 30th. Included are some exciting news from the meeting courtesy of Mark Harrington, Executive Director of the Treatment Action Group (TAG).
TB R&D Weekly Update: SQ109 and PNU Compounds Additive
In this week’s article, we look at two drugs in our Global TB Drug Pipeline and how they interact with each other: SQ109 (class: Ethylenediamines, Sequella) and PNU-100480 (called Sutezolid, class: Oxazolidinone, Pfizer). Additional links to TB R&D news are included.
TB R&D Weekly Update: TDR Tuberculosis Strain Bank
This week we highlight an article looking at the TDR Tuberculosis Strain Bank and its utility. Additional links to TB R&D news are included.
Posted in Faces of TB, TB Prevention and Control Strategies, Video, Voices from the Fight to Stop Tuberculosis
Kick TB Campaign: Scoring Big in South Africa and Beyond
The Kick TB Campaign is a unique project that uses the World’s most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis (TB).
TB R&D Weekly Update: Tyrosine Kinases as Therapeutic Targets against TB
This week’s article looks at host factors that contribute to the ability of Mycobacterium tuberculosis (Mtb) to enter and survive within macrophages. The authors explore the role of tyrosine kinases (TKs) as a mediator for Mtb and the use of an inhibitor of TKs to act against Mtb and related bacteria. Additional links to TB R&D news is included
TB R&D Weekly Update: Progress in Development of New TB Drugs
During last week, the Stop TB Partnership Working Group on New Drugs had a successful annual meeting in Lille, France, in conjunction with the 42nd Union World Conference. There were quite a few updates to the Global TB Drugs Pipeline showing progress toward the goal of better treatment for TB in all patient populations. Additional links to TB R&D news are included.
TB R&D Weekly Update: Podcast Interview with Dr. Sanjib Bhakta
This week’s interview is with Dr. Sanjib Bhkata who is Head of Mycobacteria Research Laboratory, Microbiology, Department of Biological Sciences, Institute of Structural and Molecular Biology at the Birbeck University of London. Dr. Bhakta’s Laboratory has developed an innovative method for screening compounds that is more efficient and just as accurate as more widely used methods. Additional links to TB R&D news are included.
TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop
On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development. Additional links to TB R&D are included.
TB R&D Weekly Update: New Target Identified for Pyrazinamide
This week we highlight an article published out of Ying Zhang’s laboratory at Johns Hopkins University that puts forth a new model for the mode of action of pyrazinamide (PZA) and as well as suggest trans-translation as a potential target to consider in the development of new drugs for TB. Additional links to TB R&D news are included.
-
Toppix TB News- Editorial: Lives at risk if the U.S. shortchanges Global Fund 4 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- WHO says TB in Russia displays highest known drug resistance 3 Feb 2012
- Media outlets examine Global Fund's future as it enters second decade 3 Feb 2012
